Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Kennedy Trust for Rheumatology Research (KTRR) has pledged a minimum of £20M over five years to the Kennedy Institute of Rheumatology at the University of Oxford to support pioneering research into chronic inflammatory disease.

 

Support from the Kennedy Trust has allowed us to attract exciting new investigators, establish new technologies, and develop an outstanding graduate training programme.
- Professor Fiona Powrie

The support from the KTRR will further the Kennedy Institute's ambition to harness discovery research and identification of disease pathways for application in the clinic, driving innovative new therapies to benefit patients.

Director of the Institute Professor Fiona Powrie says: "I am delighted that the Kennedy Trust have agreed to extend funding for the Institute for a further five years. With their support we have been able to attract exciting new investigators, establish new technologies, and develop an outstanding graduate training programme.

The renewed, significant funding will allow us to deliver the next phase of our strategy, including capacity building in imaging, microbiome science, informatics, and clinical research to bridge the gap between basic and translational research."

The new agreement extends the KTRR's support to the Institute beyond the current agreement which expires in 2021. The funding is awarded through individual grants and subjected to independent review on a regular basis.

Pierre Espinasse, KTRR's General Manager , says: The quality of the work undertaken at the Institute since its move to Oxford is hugely impressive and the Trust is delighted to be able to reaffirm its longterm commitment to supporting the Institute through this new agreement.

The KTRR funded the Kennedy Institute's move to Oxford from London in 2013, contributing £22M to the new building located on the University of Oxford's Old Road Campus, as well as a £5M equipment grant.

The initial agreement also committed £3M support per annum from 2011-2021 enabling the recruitment of new faculty to the Institute, as well as the development of state-of-the-art technology platforms to support key areas of research.

More broadly, the KTRR provides financial support for scientific research into improving ill health caused by rheumatic and related musculoskeletal and inflammatory diseases, particularly in areas that could benefit from long-term coordinated support.

 

Similar stories

NIHR funding for musculoskeletal and inflammatory disease research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients.

Leducq Foundation grant boosts cardiovascular research

The Leducq Foundation has awarded $7.5 million to researchers at the University of Oxford and their collaborators to advance immunotherapy as a treatment for cardiovascular disease, the leading cause of death in the UK.

MRC funding awarded to Kennedy researchers

Two new projects led by Tal Arnon and Irina Udalova have been awarded Medical Research Council (MRC) funding.

Kennedy researchers awarded funding to improve the understanding of inflammatory bowel diseases

A new £1.5M grant from the Medical Research Council (MRC) to the Powrie Group at the Kennedy Institute will help define different pathotypes of inflammatory bowel diseases that could lead to better and more focused treatments for patients.

Wellcome Trust Investigator Award for Professor Arnon

Congratulations to Professor Arnon on her successful Wellcome Trust Investigator Award entitled: “Spatiotemporal basis of adaptive immunity in the spleen.”

Oxford researchers awarded funding to study the immune response to malaria

Professors Matthew Higgins and Michael Dustin from the University of Oxford, Prof Gavin Wright from the University of York, and Professors Shiroh Iwanaga and Hisashi Arase from Osaka University have secured a Wellcome Collaborative Award for their study “How do RIFINs and STEVORs modulate human immunity during malaria?”